Lymphoma, Large-Cell, Immunoblastic disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LYM048 MIFTS: 30	Lymphoma, Large-Cell, Immunoblastic Categories: Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Lymphoma, Large-Cell, Immunoblastic

MalaCards integrated aliases for Lymphoma, Large-Cell, Immunoblastic:

Name: Lymphoma, Large-Cell, Immunoblastic ¹⁹ ⁷⁵ ³⁶

Large Cell Immunoblastic Lymphoma ¹⁹

Lymphoma Large Cell Immunoblastic ⁵³

Immunoblastic Large-Cell Lymphoma ⁷¹

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases

See all MalaCards categories (disease lists)

External Ids:

UMLS ⁷¹ C0079746

Sources

Summaries for Lymphoma, Large-Cell, Immunoblastic

GARD: ¹⁹ A diffuse large B-cell lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, a prominent nucleolus, and abundant cytoplasm.

MalaCards based summary: Lymphoma, Large-Cell, Immunoblastic, also known as large cell immunoblastic lymphoma, is related to burkitt lymphoma and peripheral t-cell lymphoma. An important gene associated with Lymphoma, Large-Cell, Immunoblastic is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Overview of interferons-mediated signaling pathway and Immune response IL-23 signaling pathway. The drugs Iodine and Aldesleukin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and liver.

Wikipedia: ⁷⁵ Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood... more...

Sources

Related Diseases for Lymphoma, Large-Cell, Immunoblastic

Diseases related to Lymphoma, Large-Cell, Immunoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)

#	Related Disease	Score	Top Affiliating Genes
1	burkitt lymphoma	29.9	TIMP1 MYC
2	peripheral t-cell lymphoma	11.3
3	lymphoma	10.2
4	reticulosarcoma	10.2
5	lymphoma, hodgkin, classic	10.1
6	immune deficiency disease	10.1
7	anaplastic large cell lymphoma	10.1
8	richter's syndrome	10.1
9	polyclonal hypergammaglobulinemia	10.1
10	acquired immunodeficiency syndrome	10.1
11	laryngeal squamous cell carcinoma	9.7	TIMP1 MYC
12	fibrosarcoma	9.7	TIMP1 MYC
13	colon adenocarcinoma	9.7	TIMP1 MYC
14	arthritis	9.7	TIMP1 MYC
15	eye disease	9.6	TIMP1 MYC
16	connective tissue disease	9.6	TIMP1 MYC
17	dilated cardiomyopathy	9.5	TIMP1 MYC

Graphical network of the top 20 diseases related to Lymphoma, Large-Cell, Immunoblastic:

Sources

Symptoms & Phenotypes for Lymphoma, Large-Cell, Immunoblastic

Sources

Drugs & Therapeutics for Lymphoma, Large-Cell, Immunoblastic

Drugs for Lymphoma, Large-Cell, Immunoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Iodine

Approved, Investigational

Phase 3

7553-56-2

807

Aldesleukin

Approved

Phase 3

110942-02-4

Cadexomer iodine

Experimental

Phase 3

94820-09-4

Tositumomab I-131

Phase 3

Analgesics

Phase 3

Interleukin-2

Phase 3

Analgesics, Non-Narcotic

Phase 3

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Etoposide

Approved

Phase 2

33419-42-0

36462

Ondansetron

Approved, Withdrawn

Phase 2

99614-02-5

4595

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Vorinostat

Approved, Investigational

Phase 1, Phase 2

149647-78-9

5311

Vincristine

Approved, Investigational

Phase 2

2068-78-2, 57-22-7

5978

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Miconazole

Approved, Investigational, Vet_approved

Phase 1, Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 1, Phase 2

23593-75-1

2812

Mitoxantrone

Approved, Investigational

Phase 2

70476-82-3, 65271-80-9

4212

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 2

52-21-1

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

4159 6741

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Alemtuzumab

Approved, Investigational

Phase 2

216503-57-0

Topotecan

Approved, Investigational

Phase 2

123948-87-8, 119413-54-6

60699 60700

Rasburicase

Approved, Investigational

Phase 2

134774-45-1

Lomustine

Approved, Investigational

Phase 2

13010-47-4

3950

Procarbazine

Approved, Investigational

Phase 2

671-16-9

4915

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Daratumumab

Approved

Phase 2

945721-28-8

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

3003 5743

Nivolumab

Approved

Phase 2

946414-94-4

Picropodophyllin

Approved, Investigational

Phase 1, Phase 2

518-28-5, 477-47-4

10607 72435

Sodium citrate

Approved, Investigational

Phase 1, Phase 2

68-04-2

23431961

Hydrocortisone succinate

Approved

Phase 1, Phase 2

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 1, Phase 2

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 1, Phase 2

50-23-7

3640 5754

Ixazomib

Approved, Investigational

Phase 1, Phase 2

1072833-77-2

25183872

Busulfan

Approved, Investigational

Phase 2

55-98-1

2478

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Methotrexate

Approved

Phase 2

1959-05-2, 59-05-2

4112 126941

Ipilimumab

Approved

Phase 1, Phase 2

477202-00-9

Ifosfamide

Approved

Phase 2

3778-73-2

3690

Iron

Approved

Phase 2

7439-89-6

29936

Interventional clinical trials:

(show top 50) (show all 124)

#	Name	Status	NCT ID	Phase	Drugs
1	Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMTCTN0401)	Completed	NCT00329030	Phase 3	Autologous transplantation using rituxan/BEAM;Autologous transplantation using Bexxar/BEAM
2	INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation	Completed	NCT00799461	Phase 3
3	Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma	Completed	NCT00002649	Phase 3	cyclophosphamide;etoposide
4	Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies	Completed	NCT01839916	Phase 2
5	Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies	Completed	NCT00867529	Phase 2
6	Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells	Completed	NCT00795769	Phase 2	ondansetron
7	A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens	Completed	NCT00489203	Phase 2	beclomethasone dipropionate;placebo;tacrolimus;methotrexate
8	A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma	Completed	NCT00073918	Phase 2	cyclophosphamide;etoposide
9	Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial	Completed	NCT00078858	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
10	A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas	Completed	NCT00054639	Phase 2
11	A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)	Completed	NCT01110135	Phase 2	bendamustine hydrochloride;dexamethasone;etoposide
12	A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma	Completed	NCT00119392	Phase 2	cyclosporine;fludarabine phosphate;mycophenolate mofetil
13	A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil	Completed	NCT00089011	Phase 2	fludarabine phosphate;mycophenolate mofetil;tacrolimus
14	Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil	Completed	NCT00006251	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
15	Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas	Completed	NCT00002003	Phase 2	Mitoxantrone hydrochloride;Etoposide
16	Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies	Completed	NCT01093586	Phase 2	busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
17	A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial	Completed	NCT00105001	Phase 2	Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
18	Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation	Completed	NCT00049504	Phase 2	cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
19	A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma	Completed	NCT00006473	Phase 2	oxaliplatin
20	A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma	Completed	NCT00601718	Phase 1, Phase 2	vorinostat;ifosfamide;carboplatin;etoposide
21	A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma	Completed	NCT00131937	Phase 2	sorafenib tosylate
22	A Phase II Study of CCI-779 in B-cell Lymphoma and CLL	Completed	NCT00290472	Phase 2	temsirolimus
23	Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial	Completed	NCT00040846	Phase 2	fludarabine phosphate;mycophenolate mofetil;cyclosporine
24	A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies	Completed	NCT00005811	Phase 2	topotecan hydrochloride
25	Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial	Completed	NCT00118352	Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
26	A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies	Completed	NCT00072514	Phase 2	gemcitabine hydrochloride;carboplatin;dexamethasone
27	A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy	Completed	NCT00057811	Phase 2	doxorubicin hydrochloride;cyclophosphamide;methotrexate;rasburicase;leucovorin calcium;prednisone;methylprednisolone;cytarabine;etoposide;vincristine sulfate;hydrocortisone sodium succinate
28	A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma	Completed	NCT00049036	Phase 2	etoposide;doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide
29	A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease	Completed	NCT00003210	Phase 2
30	Phase II Study of MK-2206 in Patients With Relapsed Lymphoma	Completed	NCT01258998	Phase 2	Akt inhibitor MK2206
31	A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation	Completed	NCT01529827	Phase 2	fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
32	High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma	Completed	NCT01177371	Phase 2	busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
33	A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation	Completed	NCT01789255	Phase 2	vorinostat;tacrolimus;cyclosporine;methotrexate
34	Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa	Completed	NCT01775475	Phase 2	cyclophosphamide;doxorubicin hydrochloride;vincristine sulfate;prednisone;lomustine;etoposide;procarbazine hydrochloride
35	A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma	Completed	NCT01193842	Phase 1, Phase 2	Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate;Vorinostat
36	A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation	Completed	NCT01427881	Phase 2	cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
37	A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant	Completed	NCT01475058	Phase 1, Phase 2
38	A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors	Completed	NCT01326702	Phase 1, Phase 2	Bendamustine Hydrochloride;Veliparib
39	Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload	Completed	NCT01273766	Phase 2	deferasirox
40	A Multicenter Phase 2 Study of Belantamab Mafodotin in Relapsed or Refractory Plasmablastic Lymphoma and ALK+ Large B-cell Lymphoma	Recruiting	NCT04676360	Phase 2	Belantamab Mafodotin
41	A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells	Recruiting	NCT02797470	Phase 1, Phase 2	Carmustine;Cytarabine;Etoposide;Melphalan
42	An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Plasmablastic Lymphoma (DALYA Trial)	Recruiting	NCT04915248	Phase 2	Daratumumab;Bortezomib;Dexamethasone
43	A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies	Recruiting	NCT01760655	Phase 2	Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
44	A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas	Active, not recruiting	NCT03038672	Phase 2	Varlilumab
45	A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen	Active, not recruiting	NCT02481310	Phase 1, Phase 2	Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride;Etoposide;Ixazomib Citrate;Methotrexate;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
46	Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma	Active, not recruiting	NCT01092182	Phase 2	EPOCH-R;EPOCH-RR
47	Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas	Active, not recruiting	NCT02213913	Phase 1, Phase 2	lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
48	Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma	Terminated	NCT00089076	Phase 1, Phase 2
49	A Phase II Study of Rituximab (IND #7028) and Ifosfamide, Carboplatin and Etoposide (ICE) Chemotherapy in Children With Recurrent/Refractory B-cell (CD20+) Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia	Terminated	NCT00058461	Phase 2	ifosfamide;etoposide;carboplatin;methotrexate;cytarabine
50	RITUXIMAB FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)	Terminated	NCT01044745	Phase 2	rituximab;mycophenolate mofetil;tacrolimus;anti-thymocyte globulin;cyclophosphamide;fludarabine phosphate;busulfan

Search NIH Clinical Center for Lymphoma, Large-Cell, Immunoblastic

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Lymphoma, Large-Cell, Immunoblastic cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Lymphoma, Large-Cell, Immunoblastic:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies
	Peripheral blood stem cells for treatment of hematologic malignancies

Embryonic/Adult Cultured Cells Related to Lymphoma, Large-Cell, Immunoblastic:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells

Sources

Genetic Tests for Lymphoma, Large-Cell, Immunoblastic

Sources

Anatomical Context for Lymphoma, Large-Cell, Immunoblastic

Organs/tissues related to Lymphoma, Large-Cell, Immunoblastic:

MalaCards : Bone Marrow, T Cells, Liver, Bone, Myeloid, Lung, Spleen

Sources

Publications for Lymphoma, Large-Cell, Immunoblastic

Articles related to Lymphoma, Large-Cell, Immunoblastic:

(show all 43)

#	Title	Authors	PMID	Year
1	Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. ⁵³ ⁶²	Nador RG...Knowles DM	8695812	1996
2	Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. ⁵³ ⁶²	Kossakowska AE...Edwards DR	1421616	1992
3	Cytomorphological and immunocytochemical study of non-Hodgkin's lymphoma in pleural effusion and ascitic fluid. ⁶²	Das DK...Kapila K	17488258	2007
4	Retrospective study of 82 cases of canine lymphoma in Austria based on the Working Formulation and immunophenotyping. ⁶²	Guija de Arespacochaga A...Weissenbock H	17416237	2007
5	Hepatosplenic large cell immunoblastic lymphoma in a bottlenose dolphin (Tursiops truncatus) with high levels of polychlorinated biphenyl congeners. ⁶²	Jaber JR...Fernandez A	15737353	2005
6	Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. ⁶²	Islas-Ohlmayer M...Garcia JV	15564497	2004
7	A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. ⁶²	Intragumtornchai T...Swasdikul D	10752986	2000
8	Primary malignant lymphoma of the duodenum: report of a case. ⁶²	Shibata Y...Miura I	9951887	1998
9	Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. ⁶²	Carbone A...Dalla-Favera R	9446632	1998
10	Secondary pleural involvement by an AIDS-related anaplastic large cell (CD30+) lymphoma simulating metastatic adenocarcinoma. ⁶²	Dunphy CH...Grosso LE	9484639	1998
11	Anaplastic large-cell lymphoma (Ki-1 lymphoma) and diffuse large-cell immunoblastic lymphoma: two diagnostic problem cases. ⁶²	King JA...Tucker JA	9491216	1998
12	Optimal primer selection for clonality assessment by polymerase chain reaction analysis. III. Intermediate and high-grade B-cell neoplasms. ⁶²	Lombardo JF...Segal GH	8617481	1996
13	Epstein-Bar virus and progression of non-Hodgkin's lymphoma to Ki-1-positive, anaplastic large cell phenotype. ⁶²	DiGiuseppe JA...Mann RB	7675777	1995
14	B-cell chronic lymphocytic leukemia followed by high grade T-cell lymphoma. An unusual variant of Richter's syndrome. ⁶²	Lee A...Medeiros LJ	7872259	1995
15	Combined chemotherapy and radiotherapy in diffuse large cell immunoblastic lymphoma: a phase II study of CHOP/bleomycin/methotrexate alternating with ifosfamide/methotrexate/etoposide. ⁶²	Rodriguez JM...Khan AA	7542471	1995
16	Human herpesvirus-6-associated malignant lymphoma in a bone marrow transplant recipient. ⁶²	Razzaque A...Varricchio F	15566776	1994
17	Detection and characterization of Epstein-Barr virus in clinical specimens. ⁶²	Ambinder RF...Mann RB	8053485	1994
18	Endobronchial HIV associated lymphoma. ⁶²	Keys TC...Sahn SA	8016780	1994
19	Lung carcinoma mimicking malignant lymphoma: report of three cases. ⁶²	Matsui K...Masuda S	8291450	1993
20	Epstein-Barr virus and primary lung lymphoma: a study utilizing the polymerase chain reaction. ⁶²	Hytiroglou P...Morgello S	8248115	1993
21	Incidence of Epstein-Barr virus in AIDS-related lymphoma specimens. ⁶²	Samoszuk M...Ramzi E	8391077	1993
22	B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. ⁶²	Abruzzo LV...Raffeld M	8391875	1993
23	Malignant lymphomas involving the ovary. A clinicopathologic analysis of 39 cases. ⁶²	Monterroso V...Medeiros LJ	8422111	1993
24	Biologic aspects of human immunodeficiency virus-related lymphoma. ⁶²	Gaidano G...Dalla-Favera R	1457505	1992
25	[Primary brain lymphoma]. ⁶²	Stein M...Haim N	1748343	1991
26	AIDS-associated polyclonal lymphoma: identification of a new HIV-associated disease process. ⁶²	McGrath MS...Herndier B	1848889	1991
27	Definition of two distinct types of AIDS-associated non-Hodgkin lymphoma. ⁶²	Boyle MJ...Cooper DA	2265114	1990
28	Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. ⁶²	Hansmann ML...Lennert K	2591946	1989
29	[Metastatic malignant lymphoma of the skull with extradural and extracranial extension. Case report]. ⁶²	Yuki K...Kamada N	2479873	1989
30	Human immunodeficiency virus-associated large-cell immunoblastic lymphoma presenting as a perianal abscess. ⁶²	Mehta K...Pawel BR	2712677	1989
31	Primary adrenal lymphoma. ⁶²	Harris GJ...Von Hoff DD	2644013	1989
32	Relapsing large cell immunoblastic lymphoma complicating well-differentiated lymphocytic lymphoma: a report of two cases showing prolonged survival with therapy. ⁶²	Kennedy MJ...O'Briain DS	3284695	1988
33	The spectrum of human immunodeficiency virus infection in patients with factor IX deficiency (Christmas disease) ⁶²	Goldsmith JM...Green D	3037883	1987
34	Malignant lymphoma, large cell immunoblastic clear cell showing unusual histologic picture. ⁶²	Kajiwara M...Miyakawa A	2956826	1987
35	Bone marrow manifestations of peripheral T-cell lymphoma. A study of 30 cases. ⁶²	Hanson CA...McKenna RW	3490173	1986
36	Recurrent chromosome abnormalities in adult T-cell lymphomas of peripheral T-cell origin. ⁶²	Fujita K...Kamesaki H	3485582	1986
37	A case report of malignant lymphoma with Hashimoto's thyroiditis. ⁶²	Noguchi M...Ono T	3838853	1985
38	Case report 269. Diagnosis: malignant lymphoma (large cell, immunoblastic type) with widespread dissemination in the skeleton as well as lymph nodes and probably the liver and spleen. ⁶²	Klein RM...Ambinder J	6547004	1984
39	Primary lymphoma of the brain associated with AIDS. A study of one case. ⁶²	Payan MJ...Toga I	6548075	1984
40	Terminal deoxynucleotidyl transferase in non-Hodgkin's lymphoma. ⁶²	Braziel RM...Jaffe ES	6356870	1983
41	Expression of a T-cell antigen (Leu-1) by B-cell lymphomas. ⁶²	Burns BF...Rouse RV	6605688	1983
42	Malignant lymphoma, diffuse mixed small and large cell. A clinicopathologic study of 47 cases. ⁶²	Foucar K...Dick FR	6687699	1983
43	Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. ⁶²	Yunis JJ...Theologides A	7133054	1982

Sources

Genes for Lymphoma, Large-Cell, Immunoblastic

Genes related to Lymphoma, Large-Cell, Immunoblastic (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	4.93	Novoseek inferred ⁵³	8695812
2	TIMP1	TIMP Metallopeptidase Inhibitor 1	Protein Coding	4.75	Novoseek inferred ⁵³	1421616

Sources

Variations for Lymphoma, Large-Cell, Immunoblastic

Sources

Expression for Lymphoma, Large-Cell, Immunoblastic

Search GEO for disease gene expression data for Lymphoma, Large-Cell, Immunoblastic.

Sources

Pathways for Lymphoma, Large-Cell, Immunoblastic

Pathways related to Lymphoma, Large-Cell, Immunoblastic according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	11.87	TIMP1 MYC
2	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	11.85	TIMP1 MYC
3	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.29	TIMP1 MYC
4	AP-1 transcription factor network ⁶¹	10.99	TIMP1 MYC
5	IL6-mediated signaling events ⁶¹	10.61	TIMP1 MYC
6	Mammary gland development pathway - Puberty (Stage 2 of 4) ⁷⁴	9.74	TIMP1 MYC